Who
Jean Jacques Bienaime
Director
Company insider
Files Form 4 as: Director, Keros Therapeutics; Director, Ascendis Pharma A/S; Director, Immunome; Director, Incyte; Chief Executive Officer, BioMarin Pharmaceutical; Director, Immunic; Director, Intermune; Director, Portola Pharmaceuticals.
In numbers
- Trades disclosed
- 1,629
- Buys
- 59
- Sells
- 351
- Bought
- $3.9M
- Sold
- $243.7M
- Companies
- 9
- Companies where not an officer
- 8
- First trade
- 23 Apr 2001
- Last trade
- 17 Aug 2026
- Last filed
- 28 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 19 Aug 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K1,000 at $10.27 | filing |
| 17 Aug 2026filed 19 Aug 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K1,000 at $10.27 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ASND Ascendis Pharma A/SBiotechnology | SEC FORM 4 Bought | $270K1,100 at $245.85 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ASND Ascendis Pharma A/SBiotechnology | SEC FORM 4 Bought | $222K900 at $246.91 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ASND Ascendis Pharma A/SBiotechnology | SEC FORM 4 Bought | $270K1,100 at $245.85 | filing |
| 14 Aug 2026filed 18 Aug 2026 | ASND Ascendis Pharma A/SBiotechnology | SEC FORM 4 Bought | $222K900 at $246.91 | filing |
| 15 Jul 2026filed 17 Jul 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K1,000 at $10.61 | filing |
| 15 Jul 2026filed 17 Jul 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K1,000 at $10.61 | filing |
| 15 Jun 2026filed 17 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K1,000 at $10.19 | filing |
| 15 Jun 2026filed 17 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K1,000 at $10.19 | filing |
| 10 Jun 2026filed 12 Jun 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,897 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,897 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,111 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code A | —1,642 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Sold | $9,720500 at $19.44 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Sold | $194K10,000 at $19.41 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $117K6,000 at $19.48 | filing |
| 5 Jun 2026filed 9 Jun 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $68K3,500 at $19.46 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)KROS · tickerreport.com · 24 Oct 2026Comparing Keros Therapeutics (NASDAQ:KROS) and Akebia Therapeutics (NASDAQ:AKBA)KROS · themarketsdaily.com · 24 Oct 2026Head-To-Head Survey: Avalo Therapeutics (NASDAQ:AVTX) & Ascendis Pharma A/S (NASDAQ:ASND)ASND · themarketsdaily.com · 22 Oct 2026Ascendis Pharma A/S (NASDAQ:ASND) vs. Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head ReviewASND · tickerreport.com · 21 Oct 2026Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial ComparisonIMNM · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Jean Jacques Bienaime; 6 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.